Short Interest in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Decreases By 21.3%

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) saw a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 148,835 shares, a drop of 21.3% from the February 12th total of 189,121 shares. Based on an average trading volume of 129,793 shares, the short-interest ratio is currently 1.1 days. Approximately 0.8% of the shares of the company are sold short. Approximately 0.8% of the shares of the company are sold short. Based on an average trading volume of 129,793 shares, the short-interest ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ARTV shares. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Finally, Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.00.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC purchased a new position in Artiva Biotherapeutics in the third quarter valued at about $41,000. Bank of America Corp DE boosted its stake in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $91,000. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000. Finally, Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $58,000.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised several multi‑period EPS forecasts, trimming projected losses across FY2026–FY2030 (e.g., FY2026 from ($4.26) to ($4.18); FY2027 from ($1.76) to ($1.61); FY2029 from ($0.74) to ($0.66); FY2030 from ($0.41) to ($0.36)). These revisions suggest modest improvement in the firm’s modeled outlook and can be supportive for the stock.
• Positive Sentiment: HC Wainwright also upgraded near‑term quarter forecasts for Q1–Q3 2026 (Q1: ($0.96) → ($0.89); Q2: ($1.05) → ($0.94); Q3: ($1.10) → ($1.06)), indicating better-than-previously-expected operating trajectory into 2026.
• Positive Sentiment: Needham & Company LLC initiated/issued a Buy rating for ARTV, which can attract demand from growth/biotech investors and provide short‑term upward pressure. Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC
• Neutral Sentiment: The company released its full‑year 2025 financial results and business highlights on March 11; investors will parse revenue, cash runway, and program updates in the filing/press release for longer‑term implications. Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
• Neutral Sentiment: Reported short‑interest data in mid‑March shows zero shares (and NaN changes), which appears to be a reporting anomaly and is not informative about true short pressure at this time.
• Negative Sentiment: HC Wainwright cut the Q4 2026 EPS view (worse) from ($1.16) to ($1.29), signaling a potentially weaker near‑term quarter that could weigh on sentiment if guidance or results mirror that pause.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $6.18 on Monday. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $7.75. The business has a fifty day moving average of $4.77 and a two-hundred day moving average of $3.98. The company has a market cap of $152.77 million, a P/E ratio of -1.81 and a beta of 2.12.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.03. Sell-side analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.